BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 14561571)

  • 1. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
    Ang G; Feiglin D; Moses AM
    Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenously administered pamidronate in the treatment of Paget's disease of bone.
    Tucci JR; Bontha S
    Endocr Pract; 2001; 7(6):423-9. PubMed ID: 11747277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
    Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
    Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
    Ryan PJ; Gibson T; Fogelman I
    J Nucl Med; 1992 Sep; 33(9):1589-93. PubMed ID: 1517830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose pamidronate in the management of resistant Paget's disease.
    Cundy T; Wattie D; King AR
    Calcif Tissue Int; 1996 Jan; 58(1):6-8. PubMed ID: 8825232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.
    Patel S; Pearson D; Hosking DJ
    Arthritis Rheum; 1995 Oct; 38(10):1506-12. PubMed ID: 7575701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paget's disease of the bone: a report of three cases.
    Bhatt K; Balakrishnan C; Mangat G; Bajan K; Ashavaid T; Joshi VR
    J Assoc Physicians India; 2006 Jul; 54():571-4. PubMed ID: 17089908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ; Gunasekera RD
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
    Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
    Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
    Wilczek H
    Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
    Drake S; Massie JD; Postlethwaite AE; Palmieri GM
    Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
    Cantrill JA; Buckler HM; Anderson DC
    Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.